

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 7/06	A1	(11) International Publication Number: WO 98/25580 (43) International Publication Date: 18 June 1998 (18.06.98)
(21) International Application Number: PCT/US97/22587 (22) International Filing Date: 12 December 1997 (12.12.97) (30) Priority Data: 08/764,980 13 December 1996 (13.12.96) US (71) Applicant (for all designated States except US): HANDELMAN, Joseph, H. [US/US]; 26 West 61st Street, New York, NY 10023 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): STYCZYNSKI, Peter [US/US]; P.O. Box 387, Mount Airy, MD 21771 (US). AHILWALIA, Gurpreet, S. [US/US]; 8632 Stableview Court, Gaithersburg, MD 20882 (US). SHANDER, Douglas [US/US]; 16112 Howard Landing Drive, Gaithersburg, MD 20878 (US). (74) Agents: RICHARDS, John; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: REDUCTION OF HAIR GROWTH (57) Abstract Mammalian hair growth is reduced by inhibiting the activity of a matrix metalloproteinase in the skin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

REDUCTION OF HAIR GROWTH

The invention relates to reducing hair growth in mammals.

A main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic reasons.
5 For example, it is generally preferred to have hair on the scalp but not on the face.

Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic antiandrogens. These conventional procedures generally have drawbacks associated with them. Shaving, for instance, can cause nicks and cuts, and can leave a perception of an increase in the rate of hair regrowth. Shaving also can leave an undesirable stubble. Electrolysis, on the other hand, can keep a treated area free of hair for prolonged periods of time, but can be expensive, painful, and sometimes leaves scarring. Depilatory creams, though very effective, typically are not recommended for frequent use due to their high irritancy potential. Waxing and plucking can cause pain, discomfort, and poor removal of short hair. Finally, antiandrogens -- which have been used to treat female hirsutism -- can have unwanted side effects.
10
15

It has previously been disclosed that the rate and character of hair growth can be altered by applying to the skin inhibitors of certain enzymes. These inhibitors include inhibitors of 5-alpha reductase, ornithine decarboxylase, S-adenosylmethionine decarboxylase, gammaglutamyl transpeptidase, and trans-glutaminase. See, for example, Breuer et al., U.S. Pat. No. 4,885,289; Shander, U.S. Pat. No. 4,720,489; Ahluwalia, U.S. Pat. No. 5,095,007; Ahluwalia et al., U.S. Pat. No. 5,096,911; Shander et al., U.S. Pat. No. 5,132,293; and Shander et al., U.S. Pat. No. 5,143,925.
20
25

Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes which together, are capable of breaking down specific protein components of the extracellular matrix, including collagen, laminin and fibronectin. At least 9 different matrix metalloproteinases have been identified, including MMP-1 (interstitial collagenase), MMP-2, (72kD collagenase), MMP-3 (stromelysin), MMP-4 (telopeptidase), MMP-5 (collagen endopeptidase), MMP-6 (acid
30

- 2 -

matalloproteinase), MMP-7 (uterine metalloproteinase), MMP-8 (neutrophil collagenase), and MMP-9 (92kD collagenase).

Several common characteristics are shared by members of the MMP family. For example, their catalytic activity is dependent upon zinc at the active center; their secreted form can be activated by other proteinases; their cDNA sequences all show homology; they can act upon one or more components of the extracellular matrix, often with overlapping substrate specificity; and their activity can be regulated, at least in part, by endogenous inhibitors. See generally Emonard and Grimaud, *Cell. Molec. Biol.* 36:131-53, (1990); Mauch et al., *Arch. Dermatol. Res.* 287:107-14, (1994).

MMPs are present in all tissues including skin and hair follicles, although their role in these two tissues remains obscure. In general, these enzymes play a significant role in physiological processes such as re-epithelialization that occurs during wound healing. Additionally, MMPs may contribute to the pathogenesis of a variety of disease states. It also is possible that MMPs contribute to the extensive cell migration during continuous renewal that both skin and hair follicles undergo (Lafuma et al., *J. Invest. Dermatol.* 102:945-950, 1994; Inoue et al. *J. Invest. Dermatol.* 104:479-483, 1995).

Both direct and indirect inhibitors of MMPs are known. One form of indirect inhibition of MMPs involves stimulating an increase in the expression or catalytic activity of endogenous tissue-derived inhibitors of MMP. Known indirect inhibitors that apparently act via this mechanism include bromo-cyclic adenosine monophosphate; protocatechuic aldehyde (3,4-dihydroxybenzaldehyde); and estramustine (estradiol-3-bis(2-chloroethyl)carbamate).

It has now been found that unwanted mammalian (including human) hair growth -- particularly androgen-stimulated hair growth -- can be reduced by applying to the skin a composition including an inhibitor of an MMP in an amount effective to reduce hair growth. The unwanted hair growth which is reduced may be normal hair growth or hair growth that results from an abnormal or diseased condition.

Examples of inhibitors of an MMP include 1,10-phenanthraline (o-phenanthroline); batimistat also known as BB-94, [4-(N-hydroxyamino)-2R-isobutyl-

- 3 -

- 3S-(thiopen-2-ylthiomethyl)-succinyl]-L-phenylalanine-N-methylamidcarboxy-alkylamino-based compounds such as N-[-1-(R)-carboxy-3-(1,3-dihydro-2H-benz[f]isoindol-2-yl)propyl]-N', N'-dimethyl-L-leucinamide, trifluoroacetate (J. Med Chem. 36:4030-4039, 1993); marimistat (BB-2516); N-chlorotaurine;
- 5 eicosapentaenoic acid; matlystatin-B; actinonin (3-[[1-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbamoyl]-octanohydroxamic acid); N-phosphonalkyl dipeptides such as N-[N-((R)-1-phosphonopropyl)-(S)-leucyl)-(S)-phenylalanine-N-methylamide (J. Med. Chem. 37:158-169, 1994); peptidyl hydroxamic acids such as pNH₂-Bz-Gly-Pro-D-Leu-D-Ala-NHOH (Biophys. Biochem. Res. Comm. 199:1442-1446, 1994);
- 10 Ro-31-7467, also known as 2-[(5-bromo-2, 3-dihydro-6-hydroxy-1, 3-dioxo-1Hbenz[de]isoquinolin-2-yl)methyl] (hydroxy)-[phosphinyl]-N-(2-oxo-3-azacyclotridecanyl)-4-methylvaleramide; CT1166, also known as N1{N-[2-(morpholinosulphonylamino)-ethyl]-3-cyclohexyl-2-(S)-propanamidyl}-N4-hydroxy-2-(R)-[3-(4-methylphenyl)propyl]-succinamide (Biochem. J. 308:167-175, 1995);
- 15 bromocyclic-adenosine monophosphate; protocatechuic aldehyde (3,4-dihydroxybenzaldehyde); estramustine (estradiol-3-bis(2-chloroethyl)carbamate).

A particular inhibitor may inhibit more than one MMP. The inhibitor may inhibit, for example, MMP-1 (interstitial collagenase), MMP-2 (72kD collagenase), MMP-3 stromelysin, MMP-4 (telopeptidase), MMP-5 (collagen

20 endopeptidase), MMP-6 (acid metalloproteinase), MMP-7 (uterine metalloproteinase), MMP-8 (neutrophil collagenase), and/or MMP-9 (92kD collagenase). Direct and/or indirect inhibitor of an MMP may be used.

The inhibitors of the MMP preferably are incorporated in a topical composition that preferably includes a non-toxic dermatologically acceptable vehicle

25 or carrier which is adapted to be spread upon the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound. One such vehicle is disclosed in copending application PCT/US93/0506A. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.

30 The concentration of the inhibitor in the composition may be varied over a wide range up to a saturated solution, preferably from 0.1% to 30% by weight or even more; the reduction of hair growth increases as the amount of

- 4 -

inhibitor applied increases per unit area of skin. The maximum amount effectively applied is limited only by the rate at which the inhibitor penetrates the skin. The effective amounts may range, for example, from 10 to 3000 micrograms or more per square centimeter of skin.

5 The composition should be topically applied to a selected area of the body from which it is desired to reduce hair growth. For example, the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek, neck, upper lip, and chin. The composition can also be applied to the legs, arms, torso or armpits. The composition is particularly suitable for reducing the growth
10 of unwanted hair in women suffering from hirsutism or other conditions. In humans, the composition should be applied once or twice a day, or even more frequently, for at least three months to achieve a perceived reduction in hair growth. Reduction in hair growth is demonstrated when the frequency or hair removal is reduced, or the subject perceives less hair on the treated site, or
15 quantitatively, when the weight of hair removed by shaving (i.e., hair mass) is reduced.

Male intact Golden Syrian hamsters are considered acceptable models for human beard hair growth in that they display oval shaped flank organs, one on each side, each about 8 mm. in major diameter, which grow thick black and coarse
20 hair similar to human beard hair. These organs produce hair in response to androgens in the hamster. To evaluate the effectiveness of a composition including an inhibitor of an MMP, the flank organs of each of a group of hamsters are depilated by applying a thioglycolate based chemical depilatory (Surgex). To one organ of each animal 10 μ l. of vehicle alone once a day is applied, while to the
25 other organ of each animal an equal amount of vehicle containing an inhibitor of a matrix metalloproteinase is applied. After thirteen applications (one application per day for five days a week), the flank organs are shaved and the amount of recovered hair (hair mass) from each is weighed. Percent-reduction of hair growth is calculated by subtracting the hair mass (mg) value of the test compound treated side
30 from the hair mass value of the vehicle treated side; the delta value obtained is then divided by the hair mass value of the vehicle treated side, and the resultant number is multiplied by 100.

- 5 -

The above-described assay will be referred to herein as the "Golden Syrian hamster" assay. Preferred compositions provide a reduction in hair growth of at least about 25%, more preferably at least about 50%, and most preferably at least about 60% when tested in the Golden Syrian hamster assay. A number of
5 inhibitors were tested in the Golden Syrian hamster assay; the results are provided in Table 1:

Table I
Effect of Matrix Metalloproteinase Inhibitors on Hair Mass

<u>Compound</u>	<u>Vehicle</u>	<u>pH</u>	<u>Dose</u>	<u>% Reduction</u>	<u>Hair Mass (mg)</u>	
					<u>Treated</u>	<u>Vehicle Control</u>
Br-cAMP	A	4.5	10%	80 ± 6	0.42 ± .12	2.00 ± .20
Minocycline	A	4.0	10%	63 ± 6	0.82 ± .11	2.27 ± .15
Methacycline	A	4.0	10%	57 ± 9	0.68 ± .11	1.75 ± .25
Tetracycline	B	4.5	10%	56 ± 9	0.67 ± .10	1.61 ± .14
1,10-Phenanthraline	A	7.0	5%	45 ± 9	1.40 ± .24	2.51 ± .25
Protocatechuic aldehyde	A	3.5	10%	32 ± 9	0.92 ± .13	1.40 ± .23
Doxycycline	A	5.5	10%	27 ± 9	1.73 ± .22	2.44 ± .21

Vehicle A: 68% H₂O; 16% ethanol; 5% propylene glycol; 5% dipropylene glycol; 4% benzyl alcohol; 2% propylene carbonate.

Vehicle B: 50% dimethylsulfoxide; 40% ethanol; 8.75% H₂O; 1% propylene glycol dipelargonate; 0.25% propylene glycol.

- 7 -

The matrix metalloproteinases MMP-2 (72kD collagenase) and MMP-9 (92kD collagenase) were assayed in flank organ hair follicle homogenates using a zymographic assay. Zymography is an electrophoretic technique used to identify proteolytic activity in enzymes separated in polyacrylamide gels under nondenaturing conditions (Kleiner and Stetler-Stevenson, Analytical Biochemistry 218:325-329, 1994). Flank organ hair follicles were removed from untreated hamsters and homogenized in a buffer containing 25 mM Tris, pH 7.5, and 50 mM sucrose. Samples of the homogenate were added to an equal volume of zymogram sample buffer containing 63 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, and .0025% bromophenol blue. (Note: all buffers and acrylamide gels were obtained from Novex, San Diego, CA). The samples were incubated for 10 minutes at room temperature and then loaded onto a precast 10% Tris-Glycine gel with 0.1% gelatin incorporated throughout the gel. The gel was electrophoresed at 125 constant volts for about 90 minutes. The gel was incubated for 30 minutes in renaturing buffer consisting of 2.5% triton X-100 followed by incubation in developing buffer which contained 10 mM Tris-base, 40 mM Tris-HCl, 200 mM NaCl, 5 mM CaCl_2 , and 0.02% Brij 35. The developing buffer was decanted after 30 minutes and replaced with fresh buffer for incubation overnight.

For inhibition experiments, the inhibitor was included in the renaturing and development buffer steps. The gel was stained with Coomassie blue 0.25% for 1 hour and then destained overnight. Transparent bands were visualized against a blue background. MMP-2 and MMP-9 standards were supplied by Oncologix (Gaithersburg, MD). The relative degree of digestion, representing collagenase activity, was quantitated by scanning photographs of the gels using Adobe Photoshop (Adobe Systems Inc., Mountain View, CA) and IPLab Gel (Signal Analytics, Vienna, VA) software. The images were digitally inverted so that the integrations of bands would be reported as positive values. This method of analysis was standardized with respect to protein concentration. The results are Provided in Table 2 and Table 3.

- 8 -

Table II

Percent Inhibition of Flank Organ MMP-2 Collagenase Activity

		<u>Concentration</u>		
	<u>Compound</u>	<u>0.1 mM</u>	<u>0.5 mM</u>	<u>1 mM</u>
5	Tetracycline	31	64	100
	Minocycline	-	-	100
	Doxycycline	89	100	-
	Methacycline	-	-	100
	1,10-Phenanthraline	100	100	-
10	- = concentration were not tested.			

Table III

Percent Inhibition of Flank Organ MMP-9 Collagenase Activity

		<u>Concentration</u>		
	<u>Compound</u>	<u>0.1 mM</u>	<u>0.5 mM</u>	<u>1 mM</u>
15	Tetracycline	49	70	100
	Minocycline	-	-	100
	Doxycycline	28	100	-
	Methacycline	-	-	100
20	1,10-Phenanthraline	100	100	-

- = concentration were not tested.

Other embodiments are within the claims.

- 9 -

C L A I M S

1. A method of reducing mammalian hair growth which comprises selecting an area of skin from which reduced hair growth is desired; and
5 applying to said area of skin a dermatologically acceptable composition comprising an inhibitor of an MMP in an amount effective to reduce hair growth.
2. The method of claim 1, wherein said inhibitor comprises 1,10-phenanthraline.
- 10 3. The method of claim 1, wherein said inhibitor comprises batimistat.
4. The method of claim 1, wherein said inhibitor comprises marimistat.
5. The method of claim 1, wherein said inhibitor comprises N-chlorotaurine.
6. The method of claim 1, wherein said inhibitor comprises
15 eicosapentaenoic acid.
7. The method of claim 1, wherein said inhibitor comprises matlystatin-B.
8. The method of claim 1, wherein said inhibitor comprises actinonin.
9. The method of claim 1, wherein said inhibitor comprises an N-
20 phosphonalkyl dipeptide.
10. The method of claim 9, wherein said inhibitor comprises N-[N(((R)-1-phosphonopropyl)-(S)-leucyl)-(S)-phenylalanine-N-methylamide.
11. The method of claim 1, wherein said inhibitor comprises peptidyl hydroxamic acid.
- 25 12. The method of claim 11, wherein said inhibitor comprises pNH₂-Bz-Gly-Pro-D-Leu-D-Ala-NHOH.
13. The method of claim 1, wherein said inhibitor comprises 2-[(5-bromo-2,3-dihydro-6-hydroxy-1,3-dioxo-1Hbenz[de]isoquinolin-2-yl)methyl](hydroxy)-[phosphinyl]-N-(2-oxo-3-azacyclotridecanyl)-4-
30 methylvaleramide
14. The method of claim 1, wherein said inhibitor comprises an analogue of N1{N-[2-(morpholinosulphonylamino)-ethyl]-3-cyclohexyl-2-(S)-propanamidy}-

- 10 -

N4-hydroxy-2-(R)-[3-(4-methylphenyl)propyl]-succinamide.

15. The method of claim 1, wherein said inhibitor bromo-cyclic adenosine monophosphate.
16. The method of claim 1, wherein said inhibitor comprises
5 protocatechuic aldehyde.
17. The method of claim 1, wherein said inhibitor comprises estramustine.
18. The method of claim 1, wherein the concentration of said inhibitor of in said composition is between 0.1% and 30%.
- 10 19. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 25% when tested in the Golden Syrian hamster assay.
20. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 50% when tested in the Golden Syrian hamster assay.
21. The method of claim 1, wherein the composition provides a reduction
15 in hair growth of at least 60% when tested in the Golden Syrian hamster assay.
22. The method of claim 1, wherein the inhibitor is applied to the skin in an amount of from 10 to 3000 micrograms of said inhibitor per square centimeter of skin.
23. The method of claim 1, wherein said mammal is a human.
- 20 24. The method of claim 22, wherein said area of skin is on the face of the human.
25. The method of claim 22, wherein said area of skin is on a leg of the human.
26. The method of claim 22, wherein said area of skin is on an arm of
25 the human.
27. The method of claim 22, wherein said area of skin is in an armpit of the human.
28. The method of claim 22, wherein said area of skin is on the torso of the human.
- 30 29. The method of claim 22, wherein said human is a woman suffering from hirsutism.
30. A method of reducing mammalian hair growth which comprises

- 11 -

selecting an area of skin from which reduced hair growth is desired;
and

applying to said area of skin a dermatologically acceptable
composition comprising an inhibitor 72kD collagenase in an amount effective to
5 reduce hair growth.

31. A method of reducing mammalian hair growth which comprises
selecting an area of skin from which reduced hair growth is desired;
and

applying to said area of skin a dermatologically acceptable
10 composition comprising an inhibitor of 92kD collagenase in an amount effective to
reduce hair growth.

32. A method of reducing mammalian hair growth which comprises
selecting an area of skin from which reduced hair growth is desired;
and

15 applying to said area of skin a dermatologically acceptable
composition comprising a compound that increases the activity of endogenous
tissue-derived inhibitors of an MMP in an amount effective to reduce hair growth.

33. A method of reducing mammalian hair growth which comprises
selecting an area of skin from which reduced hair growth is desired;
20 and

increasing the activity of endogenous tissue-derived inhibitors in said
area of skin sufficiently to cause a reduction in hair growth.

34. A method of reducing mammalian hair growth which comprises
selecting an area of skin from which reduced hair growth is desired;
25 and

inhibiting the action of an MMP in said area of skin sufficiently to
cause a reduction in hair growth.

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/US 97/22587

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 309 086 A (EFAMOL HOLDINGS) 29 March 1989 see claim 1 see page 4, line 35-41 see example 2 ---	1,6,18, 23,32-34
X	WO 95 24921 A (INSTITUTE OF OPHTHALMOLOGY) 21 September 1995 see claims 1,3,5-7,9,10,13,16,17 see page 5, line 11-21 see page 7, line 10-30 see page 16, line 10-33 -----	1,11,18, 23,30-34

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

7 May 1998

Date of mailing of the international search report

14/05/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Peeters, J

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 97/22587

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 309086 A	29-03-89	AU 2099988 A JP 1131110 A	09-03-89 24-05-89
WO 9524921 A	21-09-95	AU 1898595 A EP 0750512 A	03-10-95 02-01-97